China FDA Approval Of Peramivir Against H7N9 Flu No Boon To Developer
This article was originally published in PharmAsia News
Executive Summary
The China FDA may have given quick approval of peramivir for treating its outbreak of H7N9 avian influenza, but the U.S.-based developer of the drug, BioCryst, had not obtained a patent in China.